Decabromodiphenyl ethane
Based on 1 Customer Validation
Decabromodiphenyl ethane (DBDPE) is a brominated flame retardant. Decabromodiphenyl ethane induces ROS-related cytotoxicity and apoptosis in human hepatoma cells, causes hepatocyte damage through oxidative stress, endoplasmic reticulum stress and decreased CYP3A expression, and accumulates and undergoes biotransformation in animal tissues. Decabromodiphenyl ethane can be used to study the environmental toxicology and biological effects of brominated flame retardants.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 84852-53-9
- Formula: C14H4Br10
- Molecular Weight:971.22
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Decabromodiphenyl ethane (DBDPE) (12.5-100 mg/L; 48 or 72 h) reduces HepG2 cell viability, induces apoptosis, and increases ROS production in a dose- and time-dependent manner. Treatment with NAC decreases DBDPE-induced ROS levels and restores cell viability[3].
Exposure to decabromodiphenyl reduces the viability of L-02 hepatocytes, induces LDH release and apoptosis, increases ROS levels, elevates MDA levels, decreases GSH content, reduces SOD activity, lowers mitochondrial membrane potential, and alters the expression of endoplasmic reticulum stress-related proteins such as PERK and IRE-1α[4]
Decabromodiphenyl ethane (50 μM; 24 h) induces oxidative stress in L-02 cells, which is characterized by increased levels of ROS and MDA, as well as decreased GSH content, SOD activity and mitochondrial membrane potential; pretreatment with NAC alleviates the above changes.
Decabromodiphenyl ethane (6.25-100 μM; 24 h) reduces the viability of L-02 human normal hepatocytes in a concentration-dependent manner and increases the release of LDH and transaminases, indicating hepatocyte injury.
Exposure to decabromodiphenyl ethane reduces CYP3A expression in L-02 cells, while pretreatment with NAC or 4-PBA can ameliorate the changes in CYP3A expression induced by DBDPE.
Exposure to decabromodiphenyl ethane induces endoplasmic reticulum stress in L-02 cells, characterized by increased expression of PERK and IRE-1α; 4-PBA, an endoplasmic reticulum stress inhibitor, reduces endoplasmic reticulum stress and apoptosis induced by DBDPE.
Decabromodiphenyl ethane (12.5-100 mg/L; 48 or 72 h) induces apoptosis in HepG2 cells, accompanied by excessive production of ROS; the ROS scavenger NAC reduces the related effects induced by DBDPE.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human normal hepatocyte L-02 cells
-
Concentration:6.25 μM, 12.5 μM, 25.0 μM, 50.0 μM, 100.0 μM
-
Incubation Time:24 h
-
Result:Caused a dose-dependent decrease in L-02 cell viability.
Reduced viability significantly at concentrations of 25.0-100.0 μM compared to control.
-
Cell Line:human normal hepatocyte L-02 cells
-
Concentration:50.0 μM
-
Incubation Time:24 h
-
Result:Increased PERK and IRE-1α protein expression levels significantly in L-02 cells.
Showed no significant effect on ATF-6 expression.
Pretreatment with 4-phenylbutyric acid attenuated the induced increases in PERK and IRE-1α.\nDecreased CYP3A protein expression significantly in L-02 cells.
Pretreatment with NAC or 4-PBA attenuated this induced decrease.
-
Cell Line:human normal hepatocyte L-02 cells
-
Concentration:50.0 μM
-
Incubation Time:24 h
-
Result:Increased the apoptosis rate of L-02 cells significantly.
Pretreatment with NAC or 4-PBA significantly reduced this induced apoptosis.
-
Cell Line:human HepG2 hepatoma cells
-
Concentration:3.125 mg/L, 6.25 mg/L, 12.5 mg/L, 25.0 mg/L, 50.0 mg/L, 100.0 mg/L
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Failed to significantly alter HepG2 cell viability relative to controls at 3.125, 6.25 mg/L across all incubation times.
Inhibited HepG2 viability in a time- and dose-dependent manner at 12.5, 25.0, 50.0, 100.0 mg/L at 48 h and 72 h, with viability decreasing as both concentration and incubation time increased.
-
Cell Line:human HepG2 hepatoma cells
-
Concentration:12.5 mg/L, 25.0 mg/L, 50.0 mg/L, 100.0 mg/L
-
Incubation Time:48 h, 72 h
-
Result:Induced apoptosis in HepG2 cells in a time- and dose-dependent manner, with significantly higher apoptotic rates compared to control groups at 12.5, 25.0, 50.0, 100.0 mg/L after 48 h and 72 h.
Exhibited higher apoptotic rates after 72 h than after 48 h at equivalent concentrations.
-
Cell Line:human HepG2 hepatoma cells
-
Concentration:12.5 mg/L, 25.0 mg/L, 50.0 mg/L, 100.0 mg/L (with 10 min pretreatment with 5 mmol/L NAC)
-
Incubation Time:72 h
-
Result:Improved HepG2 cell viability that was reduced by DBDPE exposure at 12.5, 25.0, 50.0, 100.0 mg/L after 72 h when pretreated with 5 mmol/L NAC, with significant effects observed.
-
Cell Line:human HepG2 hepatoma cells
-
Concentration:12.5 mg/L, 25.0 mg/L, 50.0 mg/L, 100.0 mg/L (with 10 min pretreatment with 5 mmol/L NAC)
-
Incubation Time:72 h
-
Result:Reduced the rate of apoptosis induced by DBDPE exposure at 12.5, 25.0, 50.0, 100.0 mg/L after 72 h when pretreated with 5 mmol/L NAC, with significant effects observed.
In Vivo
Decabromodiphenyl ethane ([14C]-DBDPE; 100 nmol/kg; oral administration; single dose; 72 h observation) exhibits low oral absorption in male B6C3F1/Tac mice, with the administered radioactivity mainly excreted in feces in unchanged form; mice show faster fecal excretion rates compared to female Sprague Dawley rats, but the overall in vivo disposition characteristics are similar in the two animal models[2].
Decabromodiphenyl ethane (100 mg/kg bw/day; p.o.; daily administration; consecutive 90 days) is detectable and undergoes biotransformation in the liver, kidney, and adipose tissue of male Sprague Dawley rats. At least 7 unknown metabolites are detected after exposure, some of which are speculated to be sulfur-containing nona-BDPE derivatives, while the debromination pathway producing lower-brominated BDPEs is not the major metabolic pathway. DBDPE exposure affects some clinical biochemical parameters, thyroid hormone levels, and the expression of related enzymes in rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (female, 10 weeks old, ~200 g)[2]
-
Dosage:100 nmol/kg
-
Administration:p.o.; single dose; 72 h observation
-
Result:More than 98% of radioactivity was recovered in feces, approximately 1% was recovered in urine, and approximately 1% was detected in assayed tissues at 72 h after oral dosing.
-
Animal Model:Rat (female Sprague Dawley, 10 weeks old, ~200 g)[2]
-
Dosage:100 nmol/kg
-
Administration:p.o.; repeated dosing for 10 days; 24 h post-final dose observation
-
Result:Radioactivity concentration in adrenal tissue was increased approximately 8-fold, and liver radioactivity concentration reached 10 pmol-eq/g after repeated oral dosing compared with 0.7 pmol-eq/g after a single dose.
-
Animal Model:Rat (female Sprague Dawley, 10 weeks old, ~200 g)[2]
-
Dosage:100 nmol/kg
-
Administration:i.v.; single dose; 72 h observation
-
Result:Approximately 26% of radioactivity was recovered in feces, and the highest tissue concentrations were observed in lung (1223 pmol-eq/g), spleen (1096 pmol-eq/g), and liver (366 pmol-eq/g).
-
Animal Model:Rat (female Sprague Dawley, 10 weeks old, ~200 g)[2]
-
Dosage:2.7 nmol/cm2
-
Administration:Dermal; single dose; 24 h observation
-
Result:Approximately 5% of radioactivity penetrated through skin, and most radioactivity was retained in muscle (3%) and adipose tissue (0.8%).
-
Animal Model:Mouse (male B6C3F1/Tac, 10 weeks old, ~20 g)[2]
-
Dosage:100 nmol/kg
-
Administration:p.o.; single dose; 72 h observation
-
Result:Radioactivity was mainly eliminated through feces, and fecal elimination was faster than that in female Sprague Dawley rats, while overall disposition characteristics were similar.
-
Animal Model:Rat (male Sprague Dawley)[1]
-
Dosage:100 mg/kg bw/day
-
Administration:p.o.; daily dosing for 90 days
-
Result:Concentrations were detected in liver, kidney, and adipose tissues, and at least seven unknown metabolites were observed after exposure.
Two metabolites were tentatively proposed as MeSO2-nona-BDPE and EtSO2-nona-BDPE, while debromination to lower brominated BDPEs was not the primary metabolic pathway.
Changes in thyroid hormone levels, clinical chemistry parameters, and enzyme mRNA expression levels were also observed.
Chemical Information
-
CAS No. 84852-53-9
-
Appearance Solid
-
Molecular Weight 971.22
-
Formula C14H4Br10
-
Color White to off-white
-
SMILES
BrC1=C(Br)C(Br)=C(CCC2=C(Br)C(Br)=C(Br)C(Br)=C2Br)C(Br)=C1Br
-
Synonyms
DBDPE; 1,2-Bis(perbromophenyl)ethane
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
H2O : < 0.1 mg/mL (insoluble)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Subchronic/Chronic Toxicity Study
A subchronic/chronic oral toxicity study detects systemic adverse effects caused by repeated administration of a test article, using mortality, clinical signs, body weight, food/water intake, ophthalmology, urinalysis, hematology, serum biochemistry, organ weights, gross necropsy, and histopathology as integrated readouts. The readout reflects dose-related physiological injury, target-organ pathology, reversibility after recovery, and derivation of NOAEL, LOAEL, or related point-of-departure values when the dataset supports them.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (300 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)